Evidence map›Paper›PMID 41948064›Full record

ReviewFrontiers in aging neuroscience2026

Interleukin-6, CD8

Rui Xu, Weizheng Song, Xiaodong Zhang

Abstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rui XuSixth People's Hospital of Chengdu, Chengdu, China.
Weizheng SongSixth People's Hospital of Chengdu, Chengdu, China.
Xiaodong ZhangSixth People's Hospital of Chengdu, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder with complex interplay between neuroinflammation and immune dysfunction. Interleukin-6 (IL-6), a pleiotropic cytokine, has emerged as a controversial player in AD pathogenesis, with conflicting roles reported in inflammation and neuroprotection. This review synthesizes genetic and mechanistic evidence linking IL-6 to AD, focusing on the mediating role of peripheral immune cells-particularly CD8

Indexed as

Alzheimer’s diseasebiomarkersCD8+ T cellsimmune-neuroendocrine interactioninterleukin-6Mendelian randomizationneuroinflammation

Identifiers

PMID41948064
PMCPMC13050903

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.